JP2022507533A5 - - Google Patents

Info

Publication number
JP2022507533A5
JP2022507533A5 JP2021526561A JP2021526561A JP2022507533A5 JP 2022507533 A5 JP2022507533 A5 JP 2022507533A5 JP 2021526561 A JP2021526561 A JP 2021526561A JP 2021526561 A JP2021526561 A JP 2021526561A JP 2022507533 A5 JP2022507533 A5 JP 2022507533A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
diazaspiro
trifluoroethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021526561A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507533A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/001224 external-priority patent/WO2020099926A1/en
Publication of JP2022507533A publication Critical patent/JP2022507533A/ja
Publication of JP2022507533A5 publication Critical patent/JP2022507533A5/ja
Priority to JP2023217954A priority Critical patent/JP2024019691A/ja
Pending legal-status Critical Current

Links

JP2021526561A 2018-11-16 2019-11-15 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 Pending JP2022507533A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023217954A JP2024019691A (ja) 2018-11-16 2023-12-25 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862768575P 2018-11-16 2018-11-16
US62/768,575 2018-11-16
PCT/IB2019/001224 WO2020099926A1 (en) 2018-11-16 2019-11-15 A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023217954A Division JP2024019691A (ja) 2018-11-16 2023-12-25 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法

Publications (2)

Publication Number Publication Date
JP2022507533A JP2022507533A (ja) 2022-01-18
JP2022507533A5 true JP2022507533A5 (https=) 2022-10-05

Family

ID=69182543

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021526561A Pending JP2022507533A (ja) 2018-11-16 2019-11-15 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
JP2023217954A Pending JP2024019691A (ja) 2018-11-16 2023-12-25 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023217954A Pending JP2024019691A (ja) 2018-11-16 2023-12-25 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法

Country Status (8)

Country Link
US (2) US11413287B2 (https=)
EP (1) EP3880203A1 (https=)
JP (2) JP2022507533A (https=)
KR (1) KR20210105343A (https=)
CN (1) CN113242736A (https=)
AU (1) AU2019382168A1 (https=)
CA (1) CA3119909A1 (https=)
WO (1) WO2020099926A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11413287B2 (en) 2018-11-16 2022-08-16 Altavant Sciences Gmbh Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
WO2020128614A1 (en) * 2018-12-17 2020-06-25 Altavant Sciences Gmbh Method for treating interstital lung disease
MX2021009055A (es) 2019-01-30 2021-10-22 Altavant Sciences Gmbh Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo.
AU2020244278A1 (en) * 2019-03-15 2021-09-30 Altavant Sciences Gmbh A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
WO2023062595A1 (en) * 2021-10-14 2023-04-20 Altavant Sciences Gmbh Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7875622B2 (en) 2007-07-11 2011-01-25 Lexicon Pharmaceuticals, Inc. Methods and compositions for treating pulmonary hypertension and related diseases and disorders
TW201245183A (en) * 2010-11-05 2012-11-16 Lexicon Pharmaceuticals Inc Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid
UA119247C2 (uk) * 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
US9399741B2 (en) 2013-10-09 2016-07-26 Uop Llc Methods and apparatuses for desulfurizing hydrocarbon streams
CA3119912A1 (en) * 2018-11-14 2020-05-22 Altavant Sciences Gmbh A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin
US11413287B2 (en) 2018-11-16 2022-08-16 Altavant Sciences Gmbh Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
WO2020128614A1 (en) * 2018-12-17 2020-06-25 Altavant Sciences Gmbh Method for treating interstital lung disease
WO2020128608A1 (en) 2018-12-17 2020-06-25 Altavant Sciences Gmbh Compound for use in a method for treating sarcoidosis-associated pulmonary hypertension
MX2021009055A (es) * 2019-01-30 2021-10-22 Altavant Sciences Gmbh Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo.
AU2020244278A1 (en) 2019-03-15 2021-09-30 Altavant Sciences Gmbh A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
CN115379825A (zh) 2020-01-31 2022-11-22 阿尔塔万特科学公司 用rodatristat治疗肺动脉高压的剂量和方法
US11937070B2 (en) 2021-07-01 2024-03-19 Tencent America LLC Layered description of space of interest
WO2023079486A1 (en) 2021-11-03 2023-05-11 Altavant Sciences Gmbh Treatment of pulmonary arterial hypertension with rodatristat and ambrisentan

Similar Documents

Publication Publication Date Title
JP2022507533A5 (https=)
JP2022525202A5 (https=)
JP7697885B2 (ja) 化合物の製剤およびそれらの使用
CA2812034C (en) Methods for concomitant treatment of theophylline and febuxostat
CN103732062A (zh) 治疗多发性硬化以及保持和/或增加髓磷脂含量的方法
CN105849100A (zh) 流感病毒复制抑制剂
JP2013056911A (ja) 運動障害の予防および/または治療剤
WO2010113840A1 (ja) ソリフェナシン非晶質体を含有した固形医薬組成物
JP7383124B2 (ja) リモノイド化合物およびdpp-4阻害剤を含有する組合せ製品
WO2010107610A1 (en) Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds
US20160175286A1 (en) Selective at2 receptor agonists for use in treatment of cachexia
JP2024019691A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
CN113784717A (zh) 一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药
JP2009541455A5 (https=)
FI3713576T3 (fi) Yhdiste kaavan (i) mukaan ja ponatinibi käytettäväksi bcr-abl-mutaatioiden kanssa esiintyvän kroonisen myelooisen leukemian hoidossa
DK164638B (da) Kombinationspraeparat af pyrimido-pyrimidiner og acetylsalicylsyre og/eller deres farmaceutisk acceptable salte, fremgangsmaade til dets fremstilling samt anvendelse af pyrimido-pyrimidiner og acetylsalicylsyre og/eller salte deraf sammen med farmaceutiske baerere til fremstilling af et kombinationspraeparat
JPWO2014129513A1 (ja) 潰瘍性大腸炎の予防または治療剤と新規フラーレン誘導体
CN100372533C (zh) 腹泻为主大肠激惹综合征的治疗制剂
TW201206431A (en) Association of xanthine oxidase inhibitors and metformin and use thereof
JP2022518288A5 (https=)
JP5376785B2 (ja) 医薬組成物
JP2010536827A (ja) ある種の炎症性障害の治療に有用なカルボニルアミノ誘導体
JP2018035165A (ja) S−(+)−フルルビプロフェンを含む原薬の調製物、医薬組成物、そして剤形
KR20060130619A (ko) 유기 화합물의 조합물
CH629667A5 (fr) Composition pharmaceutique agissant sur la motricite gastro-intestinale.